27,132 Shares in Novo Nordisk A/S $NVO Bought by Vise Technologies Inc.

Vise Technologies Inc. purchased a new stake in Novo Nordisk A/S (NYSE:NVO) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 27,132 shares of the company’s stock, valued at approximately $1,873,000.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Revolve Wealth Partners LLC boosted its position in Novo Nordisk A/S by 8.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after acquiring an additional 200 shares during the last quarter. Xponance Inc. lifted its position in shares of Novo Nordisk A/S by 5.0% in the first quarter. Xponance Inc. now owns 3,314 shares of the company’s stock worth $230,000 after purchasing an additional 158 shares in the last quarter. Bleakley Financial Group LLC boosted its holdings in Novo Nordisk A/S by 0.9% during the first quarter. Bleakley Financial Group LLC now owns 70,718 shares of the company’s stock worth $4,911,000 after purchasing an additional 625 shares during the last quarter. Hohimer Wealth Management LLC acquired a new position in Novo Nordisk A/S during the first quarter worth $588,000. Finally, Apollon Wealth Management LLC grew its position in Novo Nordisk A/S by 11.2% in the first quarter. Apollon Wealth Management LLC now owns 49,192 shares of the company’s stock valued at $3,416,000 after purchasing an additional 4,964 shares in the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Dbs Bank raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, August 22nd. Rothschild Redb raised Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 16th. Rothschild & Co Redburn upgraded Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a report on Tuesday, September 16th. Morgan Stanley cut Novo Nordisk A/S from an “overweight” rating to an “underweight” rating and reduced their price target for the company from $59.00 to $47.00 in a research report on Monday, September 29th. Finally, Weiss Ratings downgraded Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, November 5th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, nine have given a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $59.20.

Novo Nordisk A/S Stock Performance

NVO opened at $49.21 on Wednesday. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. Novo Nordisk A/S has a 12-month low of $45.05 and a 12-month high of $112.52. The business has a 50 day moving average of $54.96 and a 200-day moving average of $61.30. The stock has a market cap of $219.72 billion, a price-to-earnings ratio of 13.52, a PEG ratio of 2.33 and a beta of 0.65.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, topping analysts’ consensus estimates of $0.77 by $0.25. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%.The business had revenue of $11.74 billion for the quarter, compared to analyst estimates of $11.98 billion. Novo Nordisk A/S has set its FY 2025 guidance at EPS. On average, equities research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.